All In Biotech

Drug Trial Radar · NCT07805356

Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Investigating Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Aug 31, 2026

Primary completion

Jan 2028

Study completion Jan 2033

Sponsor

Sponsor type
Industry
First posted
Sep 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to evaluate the efficacy, safety, and tolerability of orally administered encaleret tablets in participants with chronic hypoparathyroidism (HP).

Conditions

  • Hypoparathyroidism
  • Chronic Hypoparathyroidism

Interventions

  • EncaleretDrug

    Oral tablets

  • PlaceboDrug

    Oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Responders who Achieve Both Albumin-Corrected Blood Calcium (cCa) and 24-hour Urine Calcium (UCa) Within the Protocol-defined Target RangeTime frame: Week 24

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site

    Indianapolis, Indiana · Recruiting

  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site

    Boston, Massachusetts · Recruiting

  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site

    Reno, Nevada · Recruiting

  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site

    Greenville, North Carolina · Recruiting

  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site

    Morehead City, North Carolina · Recruiting

  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site

    Columbus, Ohio · Recruiting

  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site

    Philadelphia, Pennsylvania · Recruiting

  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site

    El Paso, Texas · Recruiting

  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site

    Oakville, Ontario, Canada · Recruiting

  • Calcilytix Therapeutics, Inc., a BridgeBio Company, Investigational Site

    Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.